This project is an IMI project co-funded by Horizon 2020

01/01/2020 – 31/12/2024 (5 years)



Medizinische Universitat Graz, Austria

Din Deutsches Institut Fuer Normung E.V., Germany

Universita Degli Studi Di Firenze, Italy

Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands

St. Anna Kinderkrebsforschung, Austria

Universita’ Degli Studi Di Milano-Bicocca, Italy

The University Of Liverpool, Uk

European Cancer Patient Coalition, Belgium

Bioxpedia A/S, Denmark

Christian-Albrechts-Universitaet Zu Kiel, Germany

Federzione Italiana Delle Associazioni Di Volontariato In Oncologia, Italy

Organisation Of European Cancer Institutes, Belgium

The University Of Manchester, Uk

International Prevention Research Institut-Ipri Management, France

Univerza V Ljubljani, Slovenia

Technische Universitaet Muenchen, Germany

Centre Anticancereux Leon Berard, France

Helsingin Yliopisto, Finland

Why it matters

INSTAND-NGS4P is an EU-funded Pre-Commercial Procurement (PCP) project for improving cancer patient’s benefit from Next Generation Sequencing (NGS) by developing an integrated and standardized NGS workflow. For this, it will compile information from cancer gene testing, pharmacogenetics testing and e-medication in proper presentation to medical doctors for supporting therapy decision making at bedside widely applicable in health systems. The project will define unmet medical and technical needs based on an Open Market Consultation, which lays the foundation for a call for tenders addressing solution providers (companies) to develop their products to better meet user needs. Companies responding to this call will be evaluated regarding their ability to answer these users’ needs from design perspective until the product phase. The total funding allocated to companies for product development (in total 8.55 M€) will finally lead to two integrated standardized NGS workflows, including decision support.

‘’NGS has become now the method of choice for simultaneous genomic profiling of multiple cancer markers but presently still with a very low impact into clinical practice for the purpose of diagnosis and best therapeutic option for a specific patient. Bringing NGS closer to bedside and increasing the benefit for patients is the objective of INSTAND-NGS4P. To achieve this goal, ECPC will work to actively involve patients from the very beginning to establish an integrated and standardised NGS workflow and to integrate information from cancer gene testing, pharmacogenetics testing and e-medication. It’s a very important initiative to advance precision medicine and to improve patients outcome.”


Francesco de Lorenzo, ECPC President and Past Member of ECPC Scientific Committee

What ECPC does

ECPC will be strongly involved in education, training and dissemination to the public. For patients: ECPC and FAVO will prepare specific materials with adapted languages to inform patients (minor, adult and their family members) on the activities of the various aspects and stages of the project. This type of material will ensure a better understanding of the clinicians’ diagnostics by the patients and potentially by its family members (paediatrics and adult patients).

EU flag logo

This project is funded by the European Union